MX2016005734A - Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. - Google Patents
Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica.Info
- Publication number
- MX2016005734A MX2016005734A MX2016005734A MX2016005734A MX2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A MX 2016005734 A MX2016005734 A MX 2016005734A
- Authority
- MX
- Mexico
- Prior art keywords
- increase
- reduce
- iron
- patients
- ferric citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899866P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/063643 WO2015066593A1 (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016005734A true MX2016005734A (es) | 2016-11-08 |
Family
ID=53005244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016005734A MX2016005734A (es) | 2013-11-04 | 2015-01-29 | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160256486A1 (enExample) |
| EP (2) | EP3065734A4 (enExample) |
| JP (3) | JP2016535780A (enExample) |
| KR (1) | KR102392441B1 (enExample) |
| CN (1) | CN105873583A (enExample) |
| AU (1) | AU2014341975A1 (enExample) |
| BR (1) | BR112016009901A8 (enExample) |
| CA (1) | CA2928200A1 (enExample) |
| EA (1) | EA201690926A1 (enExample) |
| HK (1) | HK1223031A1 (enExample) |
| IL (1) | IL245317A0 (enExample) |
| MX (1) | MX2016005734A (enExample) |
| SG (1) | SG11201603091QA (enExample) |
| TW (2) | TWI744215B (enExample) |
| WO (1) | WO2015066593A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120046753A (ko) | 2009-07-21 | 2012-05-10 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 구연산철 투여형태 |
| KR102633597B1 (ko) | 2013-06-05 | 2024-02-06 | 트리시다, 인크. | 경구 투여를 위한 양성자-결합 중합체 |
| EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| IL322207A (en) | 2014-12-10 | 2025-09-01 | Tricida Inc | Proton-binding polymers for oral administration |
| IL262660B2 (en) | 2016-05-06 | 2024-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| IL319146A (en) | 2017-11-03 | 2025-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| MX2021004640A (es) | 2018-10-29 | 2021-05-28 | Pharmacosmos Holding As | Tratamiento de la deficiencia de hierro con carboximaltosa ferrica. |
| EA202191858A1 (ru) * | 2019-06-12 | 2021-11-12 | Фармакосмос Холдинг А/С | Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий |
| EP4347022A1 (en) * | 2021-05-27 | 2024-04-10 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE351366B (enExample) * | 1965-06-08 | 1972-11-27 | Teikoku Hormone Mfg Co Ltd | |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| NZ566743A (en) * | 2005-08-18 | 2010-07-30 | Globoasia Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| KR20080094013A (ko) * | 2006-01-30 | 2008-10-22 | 글로보아시아 엘엘씨 | 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법 |
| EP1978808B1 (en) | 2006-01-30 | 2018-08-29 | Panion & BF Biotech Inc. | Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification |
| KR20120046753A (ko) * | 2009-07-21 | 2012-05-10 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 구연산철 투여형태 |
| JP5827326B2 (ja) * | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| SG11201408521WA (en) * | 2012-06-21 | 2015-01-29 | Keryx Biopharmaceuticals Inc | Use of ferric citrate in the treatment of chronic kidney disease patients |
-
2014
- 2014-11-03 CN CN201480072217.1A patent/CN105873583A/zh active Pending
- 2014-11-03 BR BR112016009901A patent/BR112016009901A8/pt not_active Application Discontinuation
- 2014-11-03 AU AU2014341975A patent/AU2014341975A1/en not_active Abandoned
- 2014-11-03 CA CA2928200A patent/CA2928200A1/en not_active Abandoned
- 2014-11-03 SG SG11201603091QA patent/SG11201603091QA/en unknown
- 2014-11-03 EA EA201690926A patent/EA201690926A1/ru unknown
- 2014-11-03 KR KR1020167014000A patent/KR102392441B1/ko active Active
- 2014-11-03 HK HK16111332.6A patent/HK1223031A1/zh unknown
- 2014-11-03 US US15/031,678 patent/US20160256486A1/en not_active Abandoned
- 2014-11-03 JP JP2016552432A patent/JP2016535780A/ja active Pending
- 2014-11-03 WO PCT/US2014/063643 patent/WO2015066593A1/en not_active Ceased
- 2014-11-03 EP EP14858106.9A patent/EP3065734A4/en not_active Ceased
- 2014-11-03 EP EP20173867.1A patent/EP3747432A1/en active Pending
- 2014-11-04 TW TW103138244A patent/TWI744215B/zh active
- 2014-11-04 TW TW110136784A patent/TW202203910A/zh unknown
-
2015
- 2015-01-29 MX MX2016005734A patent/MX2016005734A/es unknown
-
2016
- 2016-04-27 IL IL245317A patent/IL245317A0/en unknown
-
2018
- 2018-12-11 US US16/216,772 patent/US20190307791A1/en not_active Abandoned
-
2019
- 2019-07-31 JP JP2019140640A patent/JP6828100B2/ja active Active
-
2021
- 2021-01-20 JP JP2021007091A patent/JP2021073230A/ja active Pending
-
2024
- 2024-12-31 US US19/006,830 patent/US20250360167A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015066593A1 (en) | 2015-05-07 |
| KR102392441B1 (ko) | 2022-05-02 |
| JP2019206562A (ja) | 2019-12-05 |
| US20250360167A1 (en) | 2025-11-27 |
| EP3747432A1 (en) | 2020-12-09 |
| JP2021073230A (ja) | 2021-05-13 |
| SG11201603091QA (en) | 2016-05-30 |
| TW201609088A (zh) | 2016-03-16 |
| EP3065734A4 (en) | 2017-05-17 |
| KR20160096597A (ko) | 2016-08-16 |
| US20160256486A1 (en) | 2016-09-08 |
| EA201690926A1 (ru) | 2016-09-30 |
| CA2928200A1 (en) | 2015-05-07 |
| BR112016009901A8 (pt) | 2020-04-14 |
| AU2014341975A1 (en) | 2016-05-19 |
| TW202203910A (zh) | 2022-02-01 |
| US20190307791A1 (en) | 2019-10-10 |
| HK1223031A1 (zh) | 2017-07-21 |
| JP2016535780A (ja) | 2016-11-17 |
| CN105873583A (zh) | 2016-08-17 |
| IL245317A0 (en) | 2016-06-30 |
| JP6828100B2 (ja) | 2021-02-10 |
| TWI744215B (zh) | 2021-11-01 |
| EP3065734A1 (en) | 2016-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014015615A (es) | Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. | |
| EA201690926A1 (ru) | Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек | |
| BR112017019279A2 (pt) | kits e dispositivos descartáveis para redução de oxigênio e métodos de uso dos mesmos | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| MX2016016531A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| EA201591430A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| EA201591432A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| MX2019005435A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
| Chavez et al. | New insights into the regulation of vascular permeability | |
| WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
| EA201791611A1 (ru) | Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида | |
| CL2020000069A1 (es) | Mejora de las características del suelo con compuestos lactobionatos. | |
| Shubina et al. | Effect of chronic lead intoxication on formed elements morphology and some biochemical parameters of blood plasma of white rats | |
| NZ725920A (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| ZA202209447B (en) | Use of vitamin k in combination with anticoagulants | |
| Alyavi et al. | The Effects of Torasemide on Patients with Chronic Heart Failure | |
| MX2021011854A (es) | Tratamiento conjunto antineoplasico. | |
| RU2013110191A (ru) | Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом | |
| Ashcheulova et al. | Distant apoptosis markers-FasL (CD95L) and FasR (CD95, APO-1) at hypertensive patients with prediabetes and type 2 diabetes mellitus | |
| TH149189B (th) | แอนติโดทของสารต้านการแข็งตัวของเลือด | |
| UA115257U (xx) | Спосіб визначення мікроциркуляторно-мітохондріальної енергоструктурної недостатності | |
| Colombo | Drotrecogin-α |